As TKI monotherapy is insufficient to eradicate CML LSCs, this suggests that several genes independent of BCR-ABL1 TK may be supporting these BCR-ABL1 TK-independent cells. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.